EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer

Oral Oncol. 2023 Aug:143:106465. doi: 10.1016/j.oraloncology.2023.106465. Epub 2023 Jun 21.

Authors

Min He¹, Mahesh Gouda¹, Olivier Gires²

Affiliations

¹ Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Marchioninistr. 15, 81377 Munich, Germany.
² Department of Otorhinolaryngology, Head and Neck Surgery, Grosshadern Medical Center, Ludwig-Maximilians-University, Munich, Marchioninistr. 15, 81377 Munich, Germany. Electronic address: Olivier.gires@med.uni-muenchen.de.

PMID: 37348447
DOI: 10.1016/j.oraloncology.2023.106465

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Cell Line, Tumor
Cetuximab / pharmacology
Cetuximab / therapeutic use
Drug Resistance, Neoplasm
Epithelial Cell Adhesion Molecule
ErbB Receptors
Head and Neck Neoplasms* / drug therapy
Humans

Substances

Cetuximab
Epithelial Cell Adhesion Molecule
ErbB Receptors
Antineoplastic Agents
EGFR protein, human